Partial spleen removal via laparoscopy for cirrhosis-related hypersplenism
Part of Blood & lymphatic, Digestive system clinical trials.
This study is testing a keyhole surgery to remove part of an enlarged spleen in people with cirrhosis. It aims to improve low blood counts and reduce the risk of further bleeding from stomach or esophagus veins.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cirrhosis (scarring) of the liver from any cause.
- Your spleen is enlarged and causing low blood cell counts (hypersplenism).
- You have had bleeding from enlarged veins in your esophagus or stomach (varices).
- You do not have liver cancer or any other type of cancer.
- Your liver disease is not the most severe type (Child-Pugh C).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether removing the spleen using keyhole surgery can improve “liver reserve function” in people with cirrhosis. It may be considered for patients who have an enlarged spleen and very low platelets, but it also has several safety exclusions.
This trial looks at whether a minimally invasive spleen surgery (with a specific vein-disconnection procedure) can better protect liver function in people with cirrhosis who have had variceal bleeding. It may help reduce stress on the liver after treatment, but you must meet several safety criteria.
This study looks at whether a type of keyhole spleen surgery plus cutting a large vein can improve immune function in people with cirrhosis. It may help reduce immune problems that can happen after complications like bleeding from varices (enlarged veins in the esophagus/stomach).
This study tests whether removing an enlarged spleen during minimally invasive surgery can help protect kidney function in people with cirrhosis (liver scarring). Researchers will follow participants for 2 years to see how the surgery affects their kidneys.
This study looks at how removing an enlarged spleen affects cholesterol and fat levels in people with liver cirrhosis. The goal is to understand if spleen removal can improve these blood lipid levels and help patients over a 2-year period.
This study tests whether a surgical procedure (splenectomy with azygoportal disconnection) combined with a lipid-lowering medication (LSD) can improve cholesterol levels and reduce bleeding complications in people with advanced liver disease. Researchers will follow participants for 2 years to measure changes in blood lipids and overall health.
Hear when a new Splenectomy; Status trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.